ChemPubSoc Europe

DOI: 10.1002/ejic.201600608

EurJIC European Journal of Inorganic Chemistry

Full Paper

P-Chiral Ligands

Neutral and Cationic Palladium Complexes of *P*-Stereogenic Phosphanes Bearing a Heterocyclic Substituent

Pau Clavero,[a] Arnald Grabulosa*[a] Mercè Rocamora,[a] Guillermo Muller,[a] and Mercè Font-Bardia[b]

Abstract: The coordination chemistry of 13 optically pure *P*-stereogenic diarylmonophosphanes P(Het)PhR [Het = 4-dibenzofuranyl (DBF), 4-dibenzothiophenyl (DBT), 4-dibenzothiophenyl *S*,*S*-dioxide ($DBTO_2$) and 1-thianthrenyl (TA); R = OMe, Me, *i*Pr, Fc (ferrocenyl)] to Pd-allyl moieties is described. Both neutral [PdCl(η^3-(2-methylallyl)(κP-**P**)] and cationic [Pd{η^3-(2-methylallyl)(κP-**P**)$_2$}]PF_6 complexes have been prepared. Coordination of the heteroatom of the heterocycle was only possible in the case of TA-based phosphanes; these furnished complexes of the type [Pd{η^3-(2-methylallyl)($\kappa^2 P,S$-**P**)}]PF_6 after chloride abstraction with $TlPF_6$. The crystal structure of the complex [Pd(η^3-2-methylallyl)($\kappa^2 P,S$-PPh(OMe)(1-TA)]PF_6 is reported. The neutral Pd complexes were found to be highly active in the hydrovinylation of styrene after activation with $AgBF_4$, except for the TA-based phosphanes. The cationic Pd complexes were evaluated in allylic alkylation and amination with the model substrate *rac*-*trans*-1,3-diphenylprop-2-enyl acetate (*rac*-**I**), achieving total conversions and up to 70 % *ee*.

Introduction

Although chiral diphosphanes are the most successful type of ligands of transition-metal homogeneous catalysis, for certain reactions or under certain conditions monophosphorus ligands can give better results or they can even be required, due to mechanistic restrictions. One example is the Ni- or Pd-catalysed hydrovinylation of activated olefins.[1]

In these processes, it is thought that secondary (hemilabile) interactions can play a crucial role, improving the activity and selectivity of the reaction. Several elegant examples have been provided by RajanBabu and co-workers[2] and by Franciò, Leitner and co-workers,[3] who convincingly demonstrated the importance of secondary interactions in Ni-catalysed hydrovinylation of olefins. The design of the ligand, however, is not easy, because it has to contain the appropriate Lewis base suitably located in the scaffold of the ligand to interact with the metal centre during the catalytic reaction.



Scheme 1. *P*-stereogenic phosphanes containing a heterocyclic substituent.

Very recently,[4] we described a series of monophosphorus, *P*-stereogenic ligands containing a heterocyclic substituent [4-dibenzofuryl (DBF), 4-dibenzothiophenyl (DBT), 4-dibenzothiophenyl ($DBTO_2$) and 1-thianthrenyl (TA)] designed with the aim of disposing the heteroatom of the heterocycle in a suitable position allowing it to interact with the metal atom (Scheme 1).

[a] *Departament de Química Inorgànica i Orgànica, Secció de Química Inorgànica, Universitat de Barcelona, Martí i Franquès, 1-11, 08028 Barcelona, Spain*
E-mail: arnald.grabulosa@qi.ub.es
http://www.ub.edu/inorgani/ca/index.html
[b] *Departament de Cristallografia, Mineralogia i Dipòsits Minerals, Universitat de Barcelona, Martí i Franquès, s/n, 08028 Barcelona, Spain*
E-mail: arnald.grabulosa@qi.ub.es
Supporting information and ORCID(s) from the author(s) for this article are available on the WWW under http://dx.doi.org/10.1002/ejic.201600608.

The coordination chemistry towards Ru–η^6-arene moieties and the application of the complexes to transfer hydrogenation was also described. It was found that the sulfur atoms of DBT- and TA-containing ligands were able to act in conjunction with phosphorus as bidentate ligands in a κ^2*P,S*-coordinated fashion.

In this paper we describe the coordination of these ligands to Pd–η^3-allylic moieties and the application of the obtained complexes to catalytic hydrovinylation and allylic substitution reactions.

Results and Discussion

Neutral Complexes

As previously described for other monophosphanes,[5] treatment of the well-known Pd-dimer **D** with slightly more than two equivalents of phosphane in dichloromethane yielded the expected neutral complexes **Pd1**–**13**, of the type [PdCl(η^3-2-methylallyl)(**P**)] (Scheme 2).



Scheme 2. Preparation of neutral palladium complexes **Pd1**–**13**.

The complexes were obtained as pale yellow solids, except for those containing phosphanes bearing the ferrocenyl group (**Pd8** and **Pd12**), which were red. The complexes were characterised by IR, chemical microanalysis (or MS) and multinuclear NMR in solution. As expected,[5,6] the complexes were found to exist as mixtures of two diastereomeric species in solution, due to the presence of the chiral ligand and the allyl moiety. Hence, two singlets in the $^{31}P\{^1H\}$ NMR spectra, often partially overlapped, could be observed. All of the C and H atoms of the complexes are in principle different in each diastereomer; this could be clearly seen in the duplication of signals in the part corresponding to the allyl moiety in the ^1H and ^{13}C NMR spectra of the complexes. Full details can be found in the Experimental Section. Integration of the ^{31}P and ^1H NMR spectra allows the estimation of the diastereomeric ratio in solution. It was found that this was approximately 1:1 for all complexes, except for **Pd12**, for which it was 1:1.2. Interestingly, in complexes bearing a phosphane containing the thianthryl group (**Pd3** and **Pd13**) the H atoms of the allyl group gave rise to extremely wide peaks in the ^1H NMR spectra. In addition, no peaks could be detected for the allyl group in the $^{13}C\{^1H\}$ spectra at room temperature. Low-temperature ^1H NMR spectra of **Pd13** in CD_2Cl_2 (see the Supporting Information) showed, however, that the expected allylic hydrogen atoms appeared when the spectrum was recorded at –80 °C.

Cationic Complexes

The next type of Pd complexes prepared were cationic bisphosphanes of the type [Pd(η^3-2-methylallyl)(**P**)$_2$]PF_6. As described in previous reports,[5,7] they were obtained by splitting dimer **D** with slightly more than four equivalents of phosphane in the presence of an excess of ammonium hexafluorophosphate (Scheme 3).



Scheme 3. Preparation of cationic Pd complexes **Pd1′**–**13′**.

The complexes were obtained as stable brown solids after extractive workup with water to remove inorganic salts. They were characterised by the usual techniques. The NMR spectra showed that a single species was present in solution, as previously found for analogous compounds.[5,7] The presence of the allyl group and the chirality of the phosphane makes it the case that the atoms in the molecule are all different. Therefore, two sharp doublets in the $^{31}P\{^1H\}$ NMR spectra corresponding to the two coupled phosphorus atoms ($^2J_{P,P}$ = 30–57 Hz) could be observed. In the ^{13}C NMR spectra the two terminal allyl carbon atoms appeared as doublets or doublets of doublets, due to the coupling with the P atoms of the phosphanes. The differences between the ^{13}C chemical shifts of these two atoms are small (<2 ppm), as found in similar complexes.[7] In the ^1H NMR spectra, the four resonances of the allylic H atoms appeared as two broad singlets, corresponding to the *syn* protons and two doublets, corresponding to the *anti* protons ($^2J_{H,P}$ = 9–12 Hz). The preparation of **Pd4′** in pure form was not possible because it was always contaminated with around 25 % of neutral **Pd4**.

We next moved to study of the coordinative interactions between the heterocycle and the Pd centre. Following our previous report with ruthenium,[4] we treated the neutral complexes **Pd7** and **Pd10** with thallium hexafluorophosphate in dichloromethane, and the solid obtained after the filtration of TlCl and removal of the solvent was analysed by NMR (Scheme 4).

In the case of **Pd7**, no peaks appeared in the ^{31}P NMR spectrum and the ^1H NMR spectrum was broad and uninformative, indicating that no definite species were formed. In the case of the solid obtained from **Pd10**, both ^{31}P and ^1H NMR spectra showed that it corresponded to bis(phosphane) complex **Pd10′**. The formation of this compound indicates that a symmetrisation (disproportionation) reaction yielding the bis(phosphane) and the bis(solvato) complexes had taken place, as previously reported for Pd complexes with other monophosphane ligands.[7,8]

In contrast to the unsuccessful attempts described above, the coordination of the S atom of the thianthryl group in complexes **Pd3** and **Pd13** was successfully accomplished, yielding cationic complexes **Pd3′′** and **Pd13′′** as pale yellow solids after recrystallisation (Scheme 5). It should be mentioned that the NMR of **Pd13′′** shows the presence of a small quantity of bis(phosphane) complex **Pd13′**.

The κ^2*P,S* complexation of the ligands was confirmed by the downfield shift of the ^{31}P signals [$\Delta\delta$(**Pd3′′**–**Pd3**) = 26.2 ppm;



Scheme 4. Unsuccessful attempts to force κ^2*P,O*- and κ^2*P,S*-coordination in Pd complexes of DBF- and DBT-based ligands.



Scheme 5. Successful κ^2*P,S*-coordination in Pd complexes of TA-based ligands.

$\Delta\delta$(**Pd13**''–**Pd13**) = 26.4 ppm] characteristic when a five-membered ring is formed.[9] Two peaks appeared in the $^{31}P\{^1H\}$ spectra and two sets of signals were present in the ^1H and $^{13}C\{^1H\}$ spectra, indicating that complexes **Pd3**'' and **Pd13**'' exist as mixtures of the two diastereomers, as was also the case with precursor complexes **Pd3** and **Pd13**. The ratio between the cationic complexes is roughly 60:40, meaning that the sulfur complexation step occurs with a small degree of diastereoselectivity. It is worth noting that complexes **Pd3**'' and **Pd13**'' showed well-defined NMR spectra. In the ^1H and $^{13}C\{^1H\}$ NMR spectra, the expected two sets of peaks assignable to the allyl group appear, in contrast with the cases of **Pd3** and **Pd13** (vide infra). This is probably due to the rigid κ^2*P,S*-coordination of the ligand in the cationic complexes.

For complex **Pd3**'', single crystals suitable for X-ray crystallography could be obtained. A representation of its molecular structure is given in Figure 1.

The unit cell of **Pd3**'' contains two independent molecules, corresponding to the two different isomers of the complex. They can be named as *syn* and *anti* with regard to the relative disposition between the methyl group of the allyl fragment and the methoxy group of the phosphinite. A particular feature of the structure is the expected[10] nonplanar, "butterfly" shape of the thianthryl substituent of the phosphane, which is folded along its S–S axis. Interestingly, for both isomers in the crystal the thianthrene moiety is folded such that it remains parallel to the C(20)–C(22) bond of the allyl group. The Pd atom is in a distorted square-planar environment, the interatomic distances and angles of which are similar in the two isomers present in the unit cell and also similar to those in other Pd complexes containing five-membered P,S chelate rings, such as in a complex with a 4-diphenylphosphinophenothiazine ligand described recently by Silaghi-Dumitrescu and co-workers.[11] The distance between the Pd atom and the C atom of the allyl group *trans* to the P atom is larger than with the C atom *trans* to the S atom, indicating a higher *trans* influence of the phosphinite group relative to the thioether group. It should be



Figure 1. ORTEP representation (thermal ellipsoids drawn at 50 % probability level, H atoms and PF_6^- anions removed for clarity) of *anti*-**Pd3**'' (left) and *syn*-**Pd3**'' (right). Interatomic distances [Å] and angles [°] for *anti*-**Pd3**'': Pd(1A)–C(19A), 2.107(11); Pd(1A)–C(20A), 2.212(10); Pd(1A)–C(21A), 2.211(10); P(1A)–Pd(1A)–C(19A), 98.9(3); C(19A)–Pd(1A)–C(21A), 65.9(4); C(21A)–Pd(1A)–S(1A), 106.7(3); S(1A)–Pd(1A)–P(1A), 88.18(9); C(1A)–S(1A)–C(12A), 100.3(4); C(6A)–S(2A)–C(7A), 100.9(5). For *syn*-**Pd3**'': Pd(1B)–C(19B), 2.238(10); Pd(1B)–C(20B), 2.167(9); Pd(1B)–C(21B), 2.210(11); P(1B)–Pd(1B)–C(21B), 98.8(3); C(21B)–Pd(1B)–C(19B), 66.8(4); C(19B)–Pd(1B)–S(1B), 105.2(3); S(1B)–Pd(1B)–P(1B), 88.65(8); C(1B)–S(1B)–C(12B), 100.4(5); C(6B)–S(2B)–C(7B), 102.0(4).

pointed out that the S atom coordinated to Pd is a stereogenic centre and that each of the molecules in the crystal structure has a different absolute configuration.

The complexation studies described here with the Pd–η^3-methallyl moiety can be compared with analogous recently described studies with the Ru–η^6-arene moiety.[4] For the Ru systems it was found that both DBT- and TA-based phosphanes effectively coordinated to the Ru atom in a κ^2*P*,*S*-mode but the DBF-based ligands did not. This shows that with the systems studied, the DBF-based phosphanes have the weakest tendency to act as bidentate ligands, whereas the TA-based ones show the strongest tendency. The softer character of sulfur relative to oxygen and the greater flexibility of the TA group relative to DBF and DBT probably account for the differences in coordination abilities of these ligands.

Pd-Catalysed Hydrovinylation

The hydrovinylation reaction is a catalysed heterocodimerisation between ethylene and a conjugated diene.[1b,1d] This reaction is interesting because it creates a C–C bond by using ethylene, which is an inexpensive feedstock, and because the double bond incorporated into the molecule can subsequently be manipulated in a multitude of ways. In addition, because a stereogenic centre is created, the reaction can be carried out enantioselectively.[1a,1c,1d] Despite its interest, activity and selectivity issues hamper its full development. The most typical catalytic systems involve a Ni^{II} or Pd^{II} precursor stabilised with a monophosphorus ligand because for these metals bidentate ligands inhibit the reaction.[2c] The presence of groups capable of establishing secondary coordination interactions with the metal can be beneficial for the reaction, as shown by RajanBabu and co-workers[2b,12] and by Leiner and co-workers[3a,13] in Ni-based systems. The catalytically active species is thought to be a metal hydride. In general, nickel systems are more commonly used because they are very active and can be highly enantioselective but with the penalty of requiring (usually)[3b] very low temperatures. In contrast, palladium-based systems work well at room temperature.[6,14] The challenge, apart from improving the enantioselectivity, is the control of the regioselectivity of the reaction, because the same hydrovinylation catalyst tends to isomerise the initially formed 3-arylbut-2-enes to the more stable 2-arylbut-2-enes. It has been found by us[5,6,8b,14b,15] and by others[14a] that [PdCl(η^3-allyl)**P**] (**P** = monophosphorus ligand) complexes are excellent catalytic precursors of the active species after halide abstraction, so the potential of complexes **Pd1**–**13** in hydrovinylation was explored (Scheme 6).



Scheme 6. Pd-catalysed enantioselective hydrovinylation of styrene.

The activation of the catalysts was carried out with silver tetrafluoroborate in the presence of styrene. After removal of silver chloride by filtration, the solution was pressurised with ethylene at 25 °C. The results obtained are given in Table 1.

Most of the ligands produced active systems in the reaction but with very different activities depending on the substituents at the phosphorus atom. On close inspection, certain trends can be identified. In general the order of decreasing activity depending on the heterocycle is DBF >> DBT > $DBTO_2$ >> TA; indeed, the two TA-based systems are completely inactive even at 6 h reaction time (Entries 3 and 13). This order correlates quite nicely with the coordination ability of the heteroatom in the heterocycle so it is not surprising that the two TA-based phosphanes give completely inactive systems given the fact that they act as true bidentate ligands, which are known to inhibit the hydrovinylation reaction.[2c] Within the DBF- and DBT-based families of ligands the order depending on the R substituent is *t*Bu > *i*Pr > Fc >> OMe ≈ Me, which means that, roughly, the bulkier the ligand the more active the system becomes. This trend contrasts with previous results obtained with diarylphosphanes.[15c] It can be observed that except for methoxy- and methylphosphanes (Entries 1–5, 10) the change of a polycyclic aryl group[5,6,15c,16] for a heterocyclic substituent makes the system much more active but less selective in the hydrovinylation reaction. With regard to the enantioselectivities,

Table 1. Results of styrene hydrovinylation with **Pd1**–**13** complexes.

Entry[a]	Precursor	Time [h]	Conversion[b] [%]	Codimers[c] [%]	Selectivity[d] [%]	TOF[e] [h^{-1}]	*ee*[f] [%]
1	**Pd1**	2	13.3	13.3	>99	66	6 (*S*)
2	**Pd2**	4	33.2	32.9	92.6	81	<5
3	**Pd3**	6	<5	–	–	–	–
4	**Pd4**	4	18.8	18.5	> 99	50	<5
5	**Pd5**	6	55.6	55.6	73.2	91	<5
6	**Pd6**	0.5	58.6	57.6	92.6	1129	6 (*R*)
7	**Pd7**	0.5	91.4	91.4	74.9	1839	13 (*R*)
8	**Pd8**	1	67.3	67.3	80.4	667	20 (*S*)
9	**Pd9**	1	48.0	48.0	91.4	476	<5
10	**Pd10**	2	19.9	19.4	94.5	95	10 (*S*)
11	**Pd11**	1	84.5	83.9	85	823	18 (*S*)
12	**Pd12**	1	67.0	66.9	85.8	659	14 (*R*)
13	**Pd13**	6	<5	–	–	–	–

[a] Catalytic conditions: Pd complex (0.02 mmol), styrene (20 mmol), $AgBF_4$ (0.022 mmol) at 25 °C and $P \approx 15$ bar of initial pressure of ethylene in 15 mL of dichloromethane. [b] Conversion of starting styrene. [c] Total amount of codimers. [d] Percentage of 3-phenylbut-1-ene/codimers. [e] TOF values calculated from the total amount of codimers formed. [f] Enantiomeric excess of 3-phenylbut-1-ene at the stated time.

they are in the low range but comparable with those obtained with many previously reported diarylphosphanes.[5,6,15c,16] An interesting point is the inversion in the sense of enantioselection in comparison of analogous DBF and DBT phosphanes (cf. Entries 6 and 7 with 10 and 11, respectively) and in each family another inversion in comparison of the systems based on Fc-phosphanes (**Pd8** and **Pd12**) with their counterparts (cf. Entries 6, 7 with 8, 10 and 11 with 12).

Pd-Catalysed Allylic Substitution

Asymmetric allylic substitution is a benchmark reaction very often used to test new ligands, especially bidentate ones.[17] In the asymmetric version the model substrate is *rac-trans*-1,3-diphenylprop-2-enyl acetate (*rac*-**I**)[18] and two of the most typically employed nucleophiles are the carbanion derived from dimethyl malonate (DMM, alkylation), formed in situ in the presence of bis(trimethylsilyl)acetamide (BSA) and potassium acetate,[19] and benzylamine (amination), as depicted in Scheme 7.

In previous reports,[5,7] we employed Pd complexes of the type [Pd{η^3-(2-methylallyl)(PArPhR)$_2$}]PF_6 with *P*-stereogenic diarylphosphanes, obtaining complete conversions at 24 h and up to 80 % *ee* in alkylation with a phosphinite ligand at room temperature. Table 2 gives the results obtained with the precursors presented in this paper.

In the alkylation reaction, all the cationic and even neutral (Entries 4, 6, 11 and 13) Pd precursors led to full conversion after 24 h, giving the alkylation product with a wide range of enantiopurities depending on the substituents on the phosphorus ligand. It is clear that regardless of the heterocyclic substituent in the ligand those precursors containing phosphinites and methylphosphanes are bad enantioinductors (Entries 1–6 and 12), except for **Pd13′**, which is moderately enantioselective (Entry 16). With regard to the effect of the heterocycle, in general precursors with a DBF-containing ligands are less stereoselective, with the exception of **Pd8′** (Entry 11). As expected, neutral complexes provide lower but still moderate levels of stereoselection (cf. Entry 13 with 14 and 16 with 17), in line with previously published results.[7,20] The best precursor is **Pd11′** (Entry 13), the cationic complex with ligand **L11**. It is interesting to note that the same ligand was also the most stereoselective in transfer hydrogenation with Ru.[4]

The sense of the enantioinduction in the alkylation product also depends on the substituents on the phosphane. It is *S* for most of the precursors, but the sense is inverted in the case of Fc- and TA-containing precursors, which give rise to the predominant formation of the *R* enantiomer of the alkylation product. As expected, neutral complexes provide lower but still moderate levels of stereoselection (cf. Entry 13 with 14 and 16 with 17), in line with previously published results.[7,20]

In the case of allylic amination, full conversion is also reached with all the precursors except for cationic complexes **Pd3′**, **Pd8′**,

Table 2. Results of enantioselective allylic substitutions of *rac*-**I** with Pd complexes.

Entry[a]	Nucleophile	Precursor	Conversion [%][b]	*ee* [%][c]
1	DMM	**Pd1′**	>99	<5
2	DMM	**Pd2′**	>99	19 (*S*)
3	DMM	**Pd3′**	>99	6 (*R*)
4	DMM	**Pd3**	>99	6 (*S*)
5	DMM	**Pd3″**	>99	8 (*S*)
6	DMM	**Pd5′**	>99	<5
7	DMM	**Pd6′**	>99	12 (*S*)
8	DMM	**Pd6**	>99	16 (*S*)
9	DMM	**Pd7′**	>99	6 (*S*)
10	DMM	**Pd7**	>99	<5
11	DMM	**Pd8′**	>99	51 (*R*)
12	DMM	**Pd10′**	>99	<5
13	DMM	**Pd11′**	>99	70 (*S*)
14	DMM	**Pd11**	>99	58 (*S*)
15	DMM	**Pd12′**	>99	40 (*R*)
16	DMM	**Pd13′**	>99	43 (*R*)
17	DMM	**Pd13**	>99	34 (*R*)
18	DMM	**Pd13″**	>99	23 (*R*)
19	benzylamine	**Pd1′**	>99	<5
20	benzylamine	**Pd2′**	>99	<5
21	benzylamine	**Pd3′**	95	18 (*S*)
22	benzylamine	**Pd3″**	>99	9 (*S*)
23	benzylamine	**Pd5′**	>99	<5
24	benzylamine	**Pd6′**	>99	<5
25	benzylamine	**Pd6**	31	<5
26	benzylamine	**Pd7′**	>99	9 (*S*)
27	benzylamine	**Pd7**	>99	<5
28	benzylamine	**Pd8′**	88	53 (*S*)
29	benzylamine	**Pd10′**	>99	<5
30	benzylamine	**Pd11′**	>99	45 (*R*)
31	benzylamine	**Pd12′**	50	13 (*S*)
32	benzylamine	**Pd13′**	>99	38 (*S*)
33	benzylamine	**Pd13**	>99	49 (*S*)
34	benzylamine	**Pd13″**	>99	33 (*S*)

[a] Catalytic conditions for allylic alkylations with DMM: Pd complex (0.01 mmol), *rac*-**I** (1 mmol), dimethyl malonate (3 mmol), BSA (3 mmol) and KOAc (1 mg) in 5 mL of CH_2Cl_2 at room temp. for 24 h; for allylic substitutions with benzylamine: Pd complex (0.01 mmol), *rac*-**I** (1 mmol) and benzylamine (3 mmol) in 5 mL of CH_2Cl_2 at room temp. for 24 h. [b] Percentage conversion expressed as *rac*-**I** consumption, determined by NMR and HPLC. [c] Enantiomeric excesses determined by HPLC.



Scheme 7. Pd-catalysed enantioselective allylic substitution on substrate *rac*-**I**.

Pd12′ and complex **Pd6**. As expected[5] the enantioselectivities are lower, but follow approximately the same trends as for the allylic alkylation.

Conclusions

In this paper the coordination of 13 optically pure *P*-stereogenic diaryl monophosphinites and monophosphanes of the type PPh(Het)R (Het = 4-DBF, 4-DBT, 1-TA and 4-DBTO$_2$; R = OMe, Me, *i*Pr, *t*Bu, Fc) to the Pd–η^3-methallyl moiety has been studied. It has been found that the only ligands capable of acting as bidentate are those containing a 1-thianthrenyl group. The obtained Pd complexes were used in catalytic asymmetric hydrovinylation of styrene and allylic substitution on *rac*-**I** with the aim of comparing the performance of the new ligands with that of previously reported systems based on *P*-stereogenic PArPhR (Ar = polycyclic aromatic group).[5–7,15c,16] It was found that, in general, the new heterocyclic ligands give more active systems for the hydrovinylation reaction but that they are less selective towards 3-phenylbut-1-ene and none of them improves on the best enantioselectivity achieved with the previous systems. For the Pd-catalysed allylic substitution reactions, the activities and the best enantioselectivities (up to 70 % *ee*) are comparable with those achieved with the published analogous precursors.

Experimental Section

General: All compounds were prepared under purified nitrogen with use of standard Schlenk and vacuum-line techniques. The solvents were purified with a solvent purification system or by standard procedures[21] and kept under nitrogen. ^{1}H, ^{13}C{^{1}H}, and ^{31}P{^{1}H} and HSQC ^{1}H-^{13}C NMR spectra were recorded with 300 and 400 MHz spectrometers and $CDCl_3$ as solvent unless otherwise specified. In the NMR spectroscopic data for the Pd-methallyl complexes the following notation has been used: *c* (*cis*) and *t* (*trans*) with regard to the phosphorus moiety and *s* (*syn*) and *a* (*anti*) with regard to the methyl group of the methallyl moiety. IR spectra were recorded in KBr and the main absorption bands are expressed in cm^{-1}. The results of elemental analyses were not accurate for all compounds, probably due to the presence of residual solvents (as shown in the NMR) or to bad combustion. In these cases, HRMS (carried out with use of electrospray ionisation) clearly reflected the purity of the complexes (see Supporting Information, with assignment of relevant peaks). Styrene hydrovinylation reactions were analysed by GC with He as a carrier gas. Allylic substitution reactions on *trans*-1,3-diphenylprop-2-enyl acetate (*rac*-**I**) were analysed by HPLC with a multidiode array detector and a OD-H chiral column (25 × 0.46 cm). The eluent in the analyses was an *n*-hexane/*i*PrOH 95:5 mixture for the alkylations and a 99:1 mixture for the aminations. Pd dimer **D**[22] and substrate *rac*-**I**[23] were prepared by literature procedures whereas other reagents were used as received from commercial suppliers.

Synthesis of the Complexes

[PdCl(η^3-C$_4$H$_7$)(L1)] (Pd1): Phosphinite **L1** (191 mg, 0.62 mmol) was dissolved in dichloromethane (20 mL), Pd dimer **D** (102 mg, 0.26 mmol) was added, and the yellow solution was stirred for 1 h. The solvent was removed under vacuum and the residue was recrystallised from dichloromethane/hexane, to furnish the title product as a pale yellow solid, yield 150 mg (57 %). ^{1}H NMR (400 MHz): δ = 8.07 (s, 1 H), 8.06 (s, 1 H), 7.97 (s, 1 H), 7.95 (s, 1 H), 7.91–7.86 (m, 4 H), 7.78–7.68 (m, 2 H), 7.43–7.46 (m, 12 H), 7.38–7.34 (m, 4 H), 4.55 (s, 1 H^{ts}), 4.53 (s, 1 H^{ts}), 3.98 (d, $^3J_{H,P}$ = 14.0 Hz, 3 H), 3.95 (d, $^3J_{H,P}$ = 12.0 Hz, 3 H), 3.63 (d, $^3J_{H,P}$ = 11.2 Hz, 1 H^{ta}), 3.60 (d, $^3J_{H,P}$ = 11.6 Hz, 1 H^{ta}), 2.93 (s, 1 H^{cs}), 2.88 (s, 1 H^{cs}), 2.71 (s, 1 H^{ca}), 2.70 (s, 1 H^{ca}), 1.94 (s, 3 H), 1.91 (s, 3 H) ppm. ^{13}C{^{1}H} NMR (101 MHz): δ = 155.9–111.8 (C, CH, Ar), 79.54 (d, $^2J_{C,P}$ = 37.3 Hz, CH_2^t), 79.36 (d, $^2J_{C,P}$ = 37.1 Hz, CH_2^t), 59.2 (s, CH_2^c), 58.7 (s, CH_2^c), 57.0 (s, 2 × CH_3), 23.2 (s, 2 × CH_3) ppm. ^{31}P{^{1}H} NMR (121 MHz): δ = +115.1 (s), +114.0 (s) ppm. IR: $\tilde{\nu}$ = 3052, 2935, 2835, 1583, 1482, 1468, 1435, 1402, 1185, 1108, 1029, 805, 757, 693 cm^{-1}. HRMS: calcd. for $C_{23}H_{22}O_2PPd$ [M – Cl] 467.0392; found 467.0397.

[PdCl(η^3-C$_4$H$_7$)(L2)] (Pd2): The procedure was the same as that used to prepare **Pd1**. Starting from **L2** (310 mg, 0.96 mmol) and dimer **D** (134 mg, 0.34 mmol) the desired complex was obtained as a yellowish solid, yield 157 mg (44 %). ^{1}H NMR (400 MHz): δ = 8.27 (t, *J* = 1.2 Hz, 1 H), 8.25 (t, *J* = 1.2 Hz, 1 H), 8.17 (m, 2 H), 7.93–7.80 (m, 4 H), 7.57 (br. m, 1 H), 7.49–7.41 (m, 7 H), 4.60 (s, 1 H^{ts}), 4.58 (s, 1 H^{ts}), 3.95 (d, $^3J_{H,P}$ = 14.0 Hz, 3 H), 3.91 (d, $^3J_{H,P}$ = 14.0 Hz, 3 H), 3.68 (d, $^3J_{H,P}$ = 11.2 Hz, 2 H^{ta}), 2.91 (br. s, 1 H^{cs}), 2.84 (br. s, 1 H^{cs}), 2.70 (br. s, 1 H^{ca}), 2.65 (br. s, 1 H^{ca}), 1.94 (s, 3 H), 1.91 (s, 3 H) ppm. ^{13}C{^{1}H} NMR (101 MHz): δ = 134.3–121.6 (C, CH, Ar), 80.5 (d, $^2J_{C,P}$ = 18.3 Hz, CH_2^t), 80.2 (d, $^2J_{C,P}$ = 19.0 Hz, CH_2^t), 59.1 (s, CH_2^c), 58.8 (s, CH_2^c), 56.7 (s, 2 × CH_3), 23.34 (s, CH_3), 23.27 (s, CH_3) ppm. ^{31}P{^{1}H} NMR (162 MHz): δ = +119.8 (s), +118.8 (s) ppm. IR: $\tilde{\nu}$ = 3051, 2933, 2835, 1436, 1376, 1103, 1079, 1028, 805, 754, 693, 585, 555 cm^{-1}. $C_{23}H_{22}ClOPPdS$ (519.31): calcd. C 53.19, H 4.27, S 6.17; found C 52.74, H 4.52, S 5.74.

[PdCl(η^3-C$_4$H$_7$)(L3)] (Pd3): The procedure was the same as that used to prepare **Pd1**. Starting from **L3** (220 mg, 0.62 mmol) and dimer **D** (87 mg, 0.22 mmol) the desired complex was obtained as a pale yellow solid, yield 220 mg (91 %). ^{1}H NMR (400 MHz): δ = 7.97 (dd, *J* = 7.6, 1.6 Hz, 1 H), 7.94 (dd, *J* = 7.2, 2.0 Hz, 1 H), 7.63–7.56 (m, 2 H), 7.47–7.35 (m, 6 H), 7.24–7.20 (m, 2 H), 3.88 (d, $^3J_{H,P}$ = 14.0 Hz, 3 H) ppm. ^{31}P{^{1}H} NMR (162 MHz): δ = +111.2 (br. s) ppm. IR: $\tilde{\nu}$ = 3058, 2923, 1634, 1435, 1382, 1101, 1028, 777, 744, 693, 569, 549, 495 cm^{-1}. $C_{23}H_{22}ClOPPdS_2$ (551.37): calcd. C 50.10, H 4.02, S 11.63; found C 50.40, H 4.21, S 11.88.

[PdCl(η^3-C$_4$H$_7$)(L4)] (Pd4): The procedure was the same as that used to prepare **Pd1**. Starting from **L4** (74 mg, 0.21 mmol) and dimer **D** (35 mg, 0.088 mmol) the desired complex was obtained as a yellow solid, yield 70 mg (72 %). ^{1}H NMR (400 MHz): δ = 8.09–8.02 (m, 4 H), 7.84–7.78 (m, 6 H), 7.67–7.62 (m, 6 H), 7.58–7.46 (m, 12 H), 4.60 (dd, *J* = 7.5, 3.2 Hz, 1 H^{ts}), 4.57 (dd, *J* = 7.5, 3.2 Hz, 1 H^{ts}), 3.93 (d, $^3J_{H,P}$ = 14.0 Hz, 3 H), 3.92 (d, $^3J_{H,P}$ = 14.0 Hz, 3 H), 3.67 (d, $^3J_{H,P}$ = 11.2 Hz, 1 H^{ta}), 3.62 (d, $^3J_{H,P}$ = 10.8 Hz, 1 H^{ta}), 3.41 (br. s, 1 H^{cs}), 3.33 (br. s, 1 H^{cs}), 2.96 (s, 1 H^{ca}), 2.69 (s, 1 H^{ca}), 2.01 (s, 3 H), 1.91 (s, 3 H) ppm. ^{13}C{^{1}H} NMR (101 MHz): δ = 156.4–121.3 (C, CH, Ar), 80.5 (d, $^2J_{C,P}$ = 12.0 Hz, CH_2^t), 80.2 (d, $^2J_{C,P}$ = 12.7 Hz, CH_2^t), 59.1 (d, $^2J_{C,P}$ = 2.3 Hz, CH_2^c), 58.5 (d, $^2J_{C,P}$ = 2.8 Hz, CH_2^c), 57.5 (d, $^2J_{C,P}$ = 2.7 Hz, CH_3), 56.9 (d, $^2J_{C,P}$ = 1.9 Hz, CH_3), 23.3 (s, 2 × CH_3) ppm. ^{31}P{^{1}H} NMR (162 MHz): δ = 126.0 (s), 124.7 (s) ppm. IR: $\tilde{\nu}$ = 3052, 2938, 1437, 1309, 1159, 1044, 764, 584, 568, 543 cm^{-1}. HRMS: calcd. for $C_{23}H_{22}O_3PPdS$ [M – Cl] 515.0056; found 515.0079.

[PdCl(η^3-C$_4$H$_7$)(L5)] (Pd5): The procedure was the same as that used to prepare **Pd1**. Starting from **L5** (189 mg, 0.65 mmol) and dimer **D** (106 mg, 0.27 mmol) the desired complex was obtained as a yellow solid, yield 204 mg (78 %). ^{1}H NMR (400 MHz): δ = 8.06 (t, *J* = 1.2 Hz, 1 H), 8.04 (t, *J* = 0.8 Hz, 1 H), 7.98 (s, 1 H), 7.97–7.96 (m, 2 H), 7.95 (m, 1 H), 7.72–7.64 (m, 4 H), 7.58 (s, 1 H), 7.56 (s, 1 H), 7.51–7.32 (m, 12 H), 4.47 (s, 1 H^{ts}), 4.45 (s, 1 H^{ts}), 3.50 (d, $^3J_{H,P}$ =

10.0 Hz, 1 H^{ta}), 3.48 (d, $^3J_{H,P}$ = 10.4 Hz, 1 H^{ta}), 2.94 (s, 1 H^{cs}), 2.87 (s, 1 H^{cs}), 2.66 (s, 1 H^{ca}), 2.58 (s, 1 H^{ca}), 2.35 (d, $^2J_{H,P}$ = 8.8 Hz, 3 H), 2.33 (d, $^2J_{H,P}$ = 9.2 Hz, 3 H), 1.95 (s, 3 H), 1.85 (s, 3 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 155.9–111.6 (C, CH, Ar), 76.9 (d, ov, CH_2^t), 76.5 (d, ov, CH_2^t), 58.9 (s, 2 × CH_2^c), 23.44 (s, CH_3), 23.36 (s, CH_3), 12.4 (m, 2 × CH_3) ppm. $^{31}P\{^1H\}$ NMR (121 MHz): δ = +5.3 (s), +4.9 (s) ppm. IR: $\tilde{\nu}$ = 3050, 2979, 2915, 1583, 1469, 1448, 1435, 1399, 1184, 894, 840, 754, 692, 554, 422 cm^{-1}. $C_{23}H_{22}ClOPPd$ (487.25): calcd. C 56.69, H 4.55; found C 57.32, H 4.78.

[PdCl(η^3-C_4H_7)(L6)] (Pd6): The procedure was the same as that used to prepare **Pd1**. Starting from **L6** (318 mg, 1.00 mmol) and dimer **D** (141 mg, 0.36 mmol) the desired complex was obtained as a yellow solid, yield 280 mg (75 %). ^1H NMR (400 MHz): δ = 8.06 (s, 1 H), 8.04 (s, 1 H), 7.97 (s, 1 H), 7.95 (s, 1 H), 7.83 (dd, *J* = 10.8, 7.6 Hz, 1 H), 7.75–7.65 (m, 6 H), 7.49–7.34 (m, 13 H), 4.44 (dd, *J* = 6.8, 3.2 Hz, 1 H^{ts}), 4.42 (dd, *J* = 6.8, 3.2 Hz, 1 H^{ts}), 3.53–3.41 (m, 2 H), 3.51 (d, $^3J_{H,P}$ = 9.6 Hz, 1 H^{ta}), 3.47 (d, $^3J_{H,P}$ = 10.0 Hz, 1 H^{ta}), 3.05 (m, 1 H^{cs}), 2.96 (m, 1 H^{cs}), 2.59 (br. s, 2 H^{ca}), 1.91 (s, 3 H), 1.77 (s, 3 H), 1.34–1.19 (m, 12 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 156.5–111.7 (C, CH, Ar), 77.70 (d, $^2J_{C,P}$ = 32.4 Hz, CH_2^t), 77.67 (d, $^2J_{C,P}$ = 32.7 Hz, CH_2^t), 59.7 (s, CH_2^c), 59.0 (s, CH_2^c), 24.9 (d, $^1J_{C,P}$ = 18.1 Hz, CH), 24.7 (d, $^1J_{C,P}$ = 18.2 Hz, CH), 23.2 (s, CH_3), 23.0 (s, CH_3), 19.2 (s, CH_3), 19.1 (s, CH_3), 18.6 (d, $^2J_{C,P}$ = 1.3 Hz, CH_3), 18.4 (s, CH_3) ppm. $^{31}P\{^1H\}$ NMR (121 MHz): δ = +28.0 (s), +27.1 (s) ppm. IR: $\tilde{\nu}$ = 3051, 2957, 2925, 2867, 1582, 1469, 1449, 1435, 1401, 1184, 757, 697, 536 cm^{-1}. $C_{25}H_{26}ClOPPd$ (515.31): calcd. C 58.27, H 5.09; found C 59.68, H 5.54.

[PdCl(η^3-C_4H_7)(L7)] (Pd7): The procedure was the same as that used to prepare **Pd1**. Starting from **L7** (203 mg, 0.61 mmol) and dimer **D** (98 mg, 0.25 mmol) the desired complex was obtained as a yellow solid, yield 150 mg (57 %). ^1H NMR (300 MHz): δ = 8.07–7.86 (m, 9 H), 7.78 (ddd, *J* = 10.5, 7.8, 1.2 Hz, 1 H), 7.49–7.34 (m, 14 H), 4.45–4.40 (m, 2 H^{ts}), 3.53 (d, *J* = 9.7 Hz, 2 H^{ta}), 2.43 (s, 1 H^{cs}), 2.25 (s, 1 H^{cs}), 2.16 (m, 1 H^{ca}), 2.12 (s, 1 H^{ca}), 1.80 (s, 3 H), 1.73 (s, 3 H), 1.54 (d, $^3J_{H,P}$ = 15.8 Hz, 9 H), 1.50 (d, $^3J_{H,P}$ = 15.9 Hz, 9 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 156.1–111.8 (C, CH, Ar), 78.3 (d, $^2J_{C,P}$ = 31.2 Hz, CH_2^t), 78.0 (d, $^2J_{C,P}$ = 31.5 Hz, CH_2^t), 61.8 (s, CH_2^c), 61.4 (s, CH_2^c), 34.9 (d, $^1J_{C,P}$ = 17.7 Hz, C), 34.5 (d, $^1J_{C,P}$ = 17.9 Hz, C), 29.26 (d, $^2J_{C,P}$ = 3.0 Hz, CH_3), 29.20 (d, $^2J_{C,P}$ = 3.2 Hz, CH_3), 22.94 (s, 2 × CH_3) ppm. $^{31}P\{^1H\}$ NMR (121 MHz): δ = +35.7 (s) ppm. IR: $\tilde{\nu}$ = 3051, 2956, 2924, 1581, 1469, 1449, 1434, 1398, 1185, 1109, 756, 698 cm^{-1}. $C_{26}H_{28}ClOPPd$ (529.33): calcd. C 58.99, H 5.33; found C 59.42, H 5.78.

[PdCl(η^3-C_4H_7)(L8)] (Pd8): The procedure was the same as that used to prepare **Pd1**. Starting from **L8** (69 mg, 0.15 mmol) and dimer **D** (25 mg, 0.064 mmol) the desired complex was obtained as a reddish solid, yield 76 mg (90 %). ^1H NMR (400 MHz): δ = 8.04–8.02 (m, 2 H), 7.97 (br. s, 1 H), 7.95 (br. s, 1 H), 7.75–7.69 (m, 4 H), 7.45–7.30 (m, 14 H), 7.27 (m, 1 H), 4.81 (s, 1 H), 4.70 (s, 1 H), 4.53 (m, 2 H^{ts}), 4.49 (s, 1 H), 4.47 (s, 1 H), 4.44 (s, 2 H), 4.35 (s, 1 H), 4.28 (s, 1 H), 4.243 (s, 5 H), 4.237 (s, 5 H), 3.65 (d, $^3J_{H,P}$ = 10.4 Hz, H^{ta}), 3.62 (d, $^3J_{H,P}$ = 10.8 Hz, H^{ta}), 2.90 (s, 1 H^{cs}), 2.83 (s, 1 H^{ca}), 2.76 (s, 1 H^{cs}), 2.58 (s, 1 H^{ca}), 1.99 (s, 3 H), 1.88 (s, 3 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 155.7–111.7 (C, CH, Ar), 78.5 (d, $^2J_{C,P}$ = 33.6 Hz, CH_2^t), 77.9 (d, $^2J_{C,P}$ = 33.6 Hz, CH_2^t), 75.3 (d, *J* = 15.6 Hz, CH), 75.1 (d, *J* = 15.5 Hz, CH), 73.9 (d, *J* = 8.9 Hz, CH), 73.8 (d, *J* = 9.1 Hz, CH), 70.1 (s, 10 CH), 61.6 (s, CH_2^c), 60.1 (s, CH_2^c), 23.14 (s, CH_3), 23.10 (s, CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +6.2 (s), +6.1 (s) ppm. IR: $\tilde{\nu}$ = 3087, 3050, 2958, 1618, 1469, 1448, 1403, 1265, 1184, 1166, 1108, 751, 698 cm^{-1}. HRMS: calcd. for $C_{32}H_{28}FeOPPd$ [M – Cl] 621.0256; found 621.0275.

[PdCl(η^3-C_4H_7)(L9)] (Pd9): The procedure was the same as that used to prepare **Pd1**. Starting from **L9** (150 mg, 0.33 mmol) and dimer **D** (52 mg, 0.13 mmol) the desired complex was obtained as a yellow solid, yield 160 mg (93 %). ^1H NMR (400 MHz): δ = 8.27 (t, *J* = 1.6 Hz, 1 H), 8.25 (t, *J* = 1.6 Hz, 1 H), 8.19 (s, 1 H), 8.17 (s, 1 H), 8.11–7.97 (m, 8 H), 7.75–7.02 (m, 2 H), 7.49–7.31 (m, 24 H), 4.55 (m, 2 H^{ts}), 3.69 (d, $^3J_{H,P}$ = 10.0 Hz, 1 H^{ta}), 3.66 (d, $^3J_{H,P}$ = 10.0 Hz, 1 H^{ta}), 3.05 (s, 1 H^{cs}), 2.86 (s, 1 H^{cs}), 2.82 (s, 1 H^{ca}), 2.70 (s, 1 H^{ca}), 2.01 (s, 3 H), 1.97 (s, 3 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 155.7–111.7 (C, CH, Ar), 78.1 (d, $^2J_{C,P}$ = 32.9 Hz, CH_2^t), 77.8 (d, $^2J_{C,P}$ = 32.9 Hz, CH_2^t), 62.8 (s, CH_2^c), 62.6 (s, CH_2^c), 23.06 (s, 2 × CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +10.4 (s), +9.3 (s) ppm. IR: $\tilde{\nu}$ = 3052, 1618, 1581, 1468, 1448, 1436, 1402, 1377, 1185, 1108, 800, 752, 656, 541 cm^{-1}. HRMS: calcd. for $C_{34}H_{26}OPPdS$ [M – Cl] 619.0471; found 619.0494. $C_{34}H_{26}ClOPPdS$ (655.47): calcd. C 62.30, S 4.89, H 4.00; found C 61.86, S 4.13, H 4.38.

[PdCl(η^3-C_4H_7)(L10)] (Pd10): The procedure was the same as that used to prepare **Pd1**. Starting from **L10** (260 mg, 0.85 mmol) and dimer **D** (130 mg, 0.33 mmol) the desired complex was obtained as a pale yellow solid, yield 200 mg (60 %). ^1H NMR (400 MHz): δ = 8.24–8.22 (m, 2 H), 8.18–8.16 (m, 2 H), 7.79 (br. m, 2 H), 7.72–7.67 (m, 4 H), 7.56–7.43 (m, 14 H), 4.55 (m, 1 H^{ts}), 4.52 (m, 1 H^{ts}), 3.57 (d, $^3J_{H,P}$ = 10.0 Hz, 2 H^{ta}), 2.95 (s, 2 H^{cs}), 2.67 (s, 1 H^{ca}), 2.55 (s, 1 H^{ca}), 2.28 (d, $^2J_{H,P}$ = 8.7 Hz, 3 H), 2.26 (d, $^2J_{H,P}$ = 8.7 Hz, 3 H), 1.94 (s, 3 H), 1.91 (s, 3 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 134.6–121.7 (C, CH, Ar), 77.8 (d, $^2J_{C,P}$ = 33.4 Hz, 2 × CH_2^t), 59.1 (s, CH_2^c), 58.6 (s, CH_2^c), 23.3 (s, 2 × CH_3), 12.2 (d, $^1J_{C,P}$ = 27.0 Hz, CH_3), 11.9 (d, $^1J_{C,P}$ = 27.1 Hz, CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +8.6 (s), +8.2 (s) ppm. IR: $\tilde{\nu}$ = 3050, 2956, 2913, 1450, 1376, 1104, 1034, 892, 754, 693, 520 cm^{-1}. $C_{23}H_{22}ClPPdS$ (503.31): calcd. C 54.88, H 4.41, S 6.37; found C 54.29, H 4.66, S 5.88.

[PdCl(η^3-C_4H_7)(L11)] (Pd11): The procedure was the same as that used to prepare **Pd1**. Starting from **L11** (461 mg, 1.38 mmol) and dimer **D** (181 mg, 0.46 mmol) the desired complex was obtained as a yellow solid, yield 255 mg (52 %). ^1H NMR (400 MHz): δ = 8.26–8.23 (m, 2 H), 8.17–8.14 (m, 2 H), 7.85 (t, *J* = 8.4 Hz, 1 H), 7.78–7.73 (m, 6 H), 7.62–7.57 (m, 3 H), 7.47–7.35 (m, 10 H), 4.50 (m, 2 H^{ts}), 3.60 (d, $^3J_{H,P}$ = 9.2 Hz, 1 H^{ta}), 3.53 (d, $^3J_{H,P}$ = 9.2 Hz, 1 H^{ta}), 3.53–3.24 (m, 2 H), 2.95 (br. s, 1 H^{cs}), 2.68 (br. s, 1 H^{cs}), 2.64 (s, 1 H^{ca}), 2.49 (s, 1 H^{ca}), 1.82 (s, 6 H), 1.41 (dd, *J* = 6.8, 4.0 Hz, 3 H), 1.36 (dd, *J* = 7.2, 4.4 Hz, 3 H), 1.25 (dd, *J* = 16.4, 6.8 Hz, 3 H), 1.18 (dd, *J* = 16.4, 6.8 Hz, 3 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 139.4–121.6 (C, CH, Ar), 79.1 (d, $^2J_{C,P}$ = 31.3 Hz, CH_2^t), 78.5 (d, $^2J_{C,P}$ = 31.0 Hz, CH_2^t), 60.3 (s, CH_2^c), 58.9 (s, CH_2^c), 25.7 (d, $^1J_{C,P}$ = 23.3 Hz, CH), 25.1 (d, $^1J_{C,P}$ = 23.6 Hz, CH), 22.96 (s, CH_3), 22.86 (s, CH_3), 19.9 (d, $^2J_{C,P}$ = 6.9 Hz, CH_3), 19.8 (d, $^2J_{C,P}$ = 5.9 Hz, CH_3), 18.5 (d, $^2J_{C,P}$ = 2.3 Hz, CH_3), 18.3 (s, CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +28.2 (s), +28.1 (s) ppm. IR: $\tilde{\nu}$ = 3048, 2958, 2925, 2866, 1435, 1374, 1097, 1079, 1034, 751, 697, 659, 585, 542, 466 cm^{-1}. HRMS: calcd. for $C_{25}H_{26}PPdS$ [M – Cl] 495.0522; found 495.0542.

[PdCl(η^3-C_4H_7)(L12)] (Pd12): The procedure was the same as that used to prepare **Pd1**. Starting from **L12** (60 mg, 0.13 mmol) and dimer **D** (21 mg, 0.053 mmol) the desired complex was obtained as a red solid, yield 68 mg (95 %). ^1H NMR (400 MHz): δ = 8.19–8.13 (m, 2 H, M + m), 8.10–8.02 (m, 2 H, M + m), 7.77–7.73 (m, 1 H, M + m), 7.48–7.41 (m, 6 H, M + m), 7.22 (dd, *J* = 10.4, 7.6 Hz, 1 H, m), 7.13 (dd, *J* = 10.4, 7.2 Hz, 1 H, M), 4.86 (br. s, 1 H, m), 4.75 (br. s, 1 H, M), 4.63 (dd, *J* = 6.4, 3.2 Hz, 1 H^{ts}, M), 4.59 (br. s, 2 H, m), 4.56 (dd, *J* = 6.8, 3.2 Hz, 1 H^{ts}, m), 4.49–4.47 (m, 2 H, M), 4.29 (s, 5 H, m), 4.28 (s, 5 H, M), 3.98 (br. s, 1 H, m), 3.92 (br. s, 1 H, M), 3.71 (d, $^3J_{H,P}$ = 9.6 Hz, 1 H^{ta}, M), 3.67 (d, $^3J_{H,P}$ = 10.0 Hz, H^{ta}, m), 2.89 (br. s, 1 H^{cs}, M), 2.80 (br. s, 1 H^{cs}, m), 2.39 (br. s, 1 H^{ca}, m), 2.15 (br. s, 1 H^{ca}, M),

2.07 (s, 3 H, M), 1.62 (s, 3 H, m) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 134.6–121.6 (C, CH, Ar), 80.0 (d, $^2J_{C,P}$ = 32.7 Hz, CH_2^t, M), 78.6 (d, $^2J_{C,P}$ = 32.3 Hz, CH_2^t, m), 76.1 (s, CH), 75.9 (s, CH), 72.2–71.5 (m, 6 × CH), 70.14 (s, 5 × CH, m), 70.09 (s, 5 × CH, M), 61.4 (d, $^2J_{C,P}$ = 1.9 Hz, CH_2^c, m), 59.5 (s, CH_2^c, M), 23.0 (s, CH_3, M), 22.9 (s, CH_3, m) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +9.4 (s, M), +9.0 (s, m) ppm. IR: $\tilde{\nu}$ = 3048, 2958, 1437, 1378, 1272, 1167, 1108, 1097, 1078, 1023, 821, 754, 736, 585, 551, 498, 478, 456, 425 cm^{-1}. HRMS: calcd. for $C_{32}H_{28}FePPdS$ [M – Cl] 637.0028; found 637.0040.

[PdCl(η^3-C_4H_7)(L13)] (Pd13): The procedure was the same as that used to prepare **Pd1**. Starting from **L13** (281 mg, 0.83 mmol) and dimer **D** (130 mg, 0.33 mmol) the desired complex was obtained as a yellow solid, yield 280 mg (79 %). ^1H NMR (400 MHz): δ = 7.71 (dd, *J* = 7.6, 1.6 Hz, 1 H), 7.68 (dd, *J* = 7.6, 1.6 Hz, 1 H), 7.59 (dt, *J* = 7.6, 1.2 Hz, 1 H), 7.51–7.41 (m, 4 H), 7.35 (dd, *J* = 7.2, 1.6 Hz, 1 H), 7.28–7.17 (m, 4 H), 2.22 (d, $^2J_{H,P}$ = 8.8 Hz, 3 H), 1.91 (s, 3 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 139.2–127.2 (C, CH, Ar), 23.2 (s, 2 × CH_3), 13.4 (d, $^1J_{C,P}$ = 27.1 Hz, CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +8.9 (br. s) ppm. IR: $\tilde{\nu}$ = 3048, 2956, 2911, 1616, 1448, 1434, 1380, 1140, 1101, 1027, 891, 836, 749, 692, 487, 444 cm^{-1}. HRMS: calcd. for $C_{23}H_{22}PPdS_2$ [M – Cl] 498.9929; found 498.9937. $C_{23}H_{22}ClPPdS_2$ (535.37): calcd. C 51.60, S 11.98, H 4.14; found C 50.33, S 11.00, H 4.44.

[Pd(η^3-C_4H_7)(L1)$_2$]PF_6 (Pd1′): Phosphinite **L1** (323 mg, 1.05 mmol), Pd dimer **D** (70 mg, 0.18 mmol) and NH_4PF_6 (171 mg, 1.05 mmol) were suspended in dichloromethane (20 mL) and stirred vigorously for 2 h. Water (20 mL) was added and the mixture was extracted with dichloromethane (3 × 10 mL). The combined organic phase was washed with water, dried with anhydrous Na_2SO_4 and filtered, and the solvent was removed under vacuum. The crude product was recrystallised from dichloromethane/hexane, yield 204 mg (62 %). ^1H NMR (400 MHz): δ = 8.00–7.89 (m, 4 H), 7.58–7.20 (m, 19 H), 7.07 (ddd, *J* = 10.4, 7.6, 1.2 Hz, 1 H), 4.06 (d, *J* = 5.6 Hz, 1 H^s), 4.04 (d, *J* = 5.6 Hz, 1 H^s), 3.66 (d, $^3J_{H,P}$ = 13.2 Hz, 3 H), 3.60 (d, $^3J_{H,P}$ = 13.2 Hz, 3 H), 3.47 (d, $^3J_{H,P}$ = 10.8 Hz, 1 H^a), 3.39 (d, $^3J_{H,P}$ = 10.8 Hz, 1 H^a), 1.80 (s, 3 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 155.6–111.5 (C, CH, Ar), 74.7 (dd, $J_{C,P}$ = 23.0, 3.6 Hz, CH_2), 74.4 (dd, $J_{C,P}$ = 25.0, 3.3 Hz, CH_2), 56.9 (d, $^2J_{C,P}$ = 6.0 Hz, CH_3), 56.8 (d, $^2J_{C,P}$ = 6.6 Hz, CH_3), 23.7 (s, CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +113.6 (d, $^2J_{P,P}$ = 56.5 Hz), +112.4 (d, $^2J_{P,P}$ = 56.5 Hz) ppm. IR: $\tilde{\nu}$ = 3061, 2956, 2872, 1585, 1469, 1448, 1404, 1264, 1185, 1110, 1035, 839 [$\nu(PF_6^-)$], 756, 695, 557 cm^{-1}. $C_{42}H_{37}F_6O_4P_3Pd$ (919.06): calcd. C 54.89, H 4.06; found C 56.52, H 4.98.

[Pd(η^3-C_4H_7)(L2)$_2$]PF_6 (Pd2′): The procedure was the same as that used to prepare **Pd1′**. Starting from **L2** (273 mg, 0.85 mmol) and dimer **D** (56 mg, 0.14 mmol) the desired complex was obtained as a brown solid, yield 177 mg (66 %). ^1H NMR (400 MHz): δ = 8.18–8.08 (m, 4 H), 7.86 (m, 1 H), 7.60–7.30 (m, 19 H), 4.32 (br. s, 1 H^s), 4.02 (br. s, 1 H^s), 3.52 (d, $^3J_{H,P}$ = 11.6 Hz, 1 H^a), 3.49 (d, $^3J_{H,P}$ = 10.4 Hz, 1 H^a), 3.47 (d, $^3J_{H,P}$ = 12.4 Hz, 3 H), 3.43 (d, $^3J_{H,P}$ = 12.4 Hz, 3 H), 1.87 (s, 3 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 141.6–121.5 (C, CH, Ar), 74.9 (dd, $J_{C,P}$ = 2.8, 2.7 Hz, CH_2), 74.6 (dd, $J_{C,P}$ = 2.8, 2.7 Hz, CH_2), 55.8 (d, $^2J_{C,P}$ = 2.1 Hz, CH_3), 55.7 (d, $^2J_{C,P}$ = 2.1 Hz, CH_3), 23.7 (s, CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +122.3 (d, $^2J_{P,P}$ = 55.4 Hz), +119.0 (d, $^2J_{P,P}$ = 54.6 Hz) ppm. IR: $\tilde{\nu}$ = 3056, 2940, 1437, 1377, 1104, 1021, 841 [$\nu(PF_6^-)$], 750, 702, 557 cm^{-1}. HRMS: calcd. for $C_{42}H_{37}O_2P_2PdS_2$ [M – PF_6] 805.0739; found 805.0755.

[Pd(η^3-C_4H_7)(L3)$_2$]PF_6 (Pd3′): The procedure was the same as that used to prepare **Pd1′**. Starting from **L3** (350 mg, 0.99 mmol) and dimer **D** (70 mg, 0.18 mmol) the desired complex was obtained as a brown solid, yield 300 mg (82 %). ^1H NMR (400 MHz): δ = 7.62–7.06 (br. m, 23 H), 6.78 (br. s, 1 H), 4.19 (br. s, 2 H^s), 3.54 (br. d, $^3J_{H,P}$ = 9.2 Hz, 3 H), 3.43 (d, $^3J_{H,P}$ = 11.2 Hz, 3 H), 3.33 (br. s, 2 H^a), 2.03 (s, 3 H) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +114.5 (d, $^2J_{P,P}$ = 56.2 Hz), +112.3 (d, $^2J_{P,P}$ = 56.1 Hz) ppm. IR: $\tilde{\nu}$ = 3054, 2945, 2838, 1450, 1435, 1382, 1251, 1140, 1102, 1027, 832 [$\nu(PF_6^-)$], 747, 696, 558 cm^{-1}. $C_{42}H_{37}F_6O_2P_3PdS_4$ (1015.30): calcd. C 49.68, H 3.67, S 12.63; found C 51.89, H 3.03, S 11.76.

[Pd(η^3-C_4H_7)(L5)$_2$]PF_6 (Pd5′): The procedure was the same as that used to prepare **Pd1′**. Starting from **L5** (80 mg, 0.28 mmol) and dimer **D** (22 mg, 0.06 mmol) the desired complex was obtained as a brownish solid, yield 86 mg (87 %). ^1H NMR (400 MHz): δ = 7.89–7.79 (m, 4 H), 7.51–7.30 (m, 16 H), 7.14–6.98 (m, 3 H), 6.68 (dd, *J* = 11.6, 7.6 Hz, 1 H), 3.95 (s, 1 H^s), 3.70 (s, 1 H^s), 3.51 (d, $^3J_{H,P}$ = 10.0 Hz, 1 H^a), 3.44 (d, $^3J_{H,P}$ = 10.0 Hz, 1 H^a), 2.18 (d, $^2J_{H,P}$ = 8.4 Hz, 3 H), 1.99 (d, $^2J_{H,P}$ = 8.8 Hz, 3 H), 1.85 (s, 3 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 155.5–111.6 (C, CH, Ar), 75.0 (d, $J_{C,P}$ = 29.4 Hz, CH_2), 74.2 (d, $J_{C,P}$ = 30.6 Hz, CH_2), 23.8 (s, CH_3), 14.8 (dd, $^1J_{C,P}$ = 28.1, 1.1 Hz, CH_3), 13.3 (dd, $^1J_{C,P}$ = 28.0, 1.9 Hz, CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +0.2 (d, $^2J_{P,P}$ = 40.5 Hz), –0.1 (d, $^2J_{P,P}$ = 40.5 Hz) ppm. IR: $\tilde{\nu}$ = 3062, 2957, 2923, 1584, 1470, 1450, 1437, 1403, 1186, 1111, 1010, 896, 843 [$\nu(PF_6^-)$], 754, 634, 557 cm^{-1}. HRMS: calcd. for $C_{42}H_{37}O_2P_2Pd$ [M – PF_6], 741.1304; found 741.1326.

[Pd(η^3-C_4H_7)(L6)$_2$]PF_6 (Pd6′): The procedure was the same as that used to prepare **Pd1′**. Starting from **L6** (370 mg, 1.16 mmol) and dimer **D** (85 mg, 0.22 mmol) the desired complex was obtained as a dark yellow solid, yield 290 mg (71 %). ^1H NMR (400 MHz): δ = 8.01–7.95 (m, 4 H), 7.48–7.21 (m, 18 H), 7.16–7.11 (m, 2 H), 4.27 (br. s, 1 H^s), 4.21 (br. s, 1 H^s), 3.42 (d, $^3J_{H,P}$ = 9.6 Hz, 1 H^a), 3.31 (d, $^3J_{H,P}$ = 9.6 Hz, 1 H^a), 2.96 (m, 1 H), 2.78 (m, 1 H), 1.74 (s, 3 H), 0.99–0.83 (m, 12 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 156.0–111.4 (C, CH, Ar), 75.0 (d, $J_{C,P}$ = 28.4 Hz, CH_2), 74.7 (d, $J_{C,P}$ = 28.4 Hz, CH_2), 28.0 (d, $^1J_{C,P}$ = 23.4 Hz, CH), 26.7 (d, $^1J_{C,P}$ = 23.5 Hz, CH), 23.0 (s, CH_3), 19.3 (d, $^2J_{C,P}$ = 3.8 Hz, CH_3), 19.1 (d, $^2J_{C,P}$ = 3.6 Hz, CH_3), 19.0 (d, $^2J_{C,P}$ = 2.4 Hz, 2 × CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +25.0 (d, $^2J_{P,P}$ = 34.2 Hz), +23.7 (d, $^2J_{P,P}$ = 34.2 Hz) ppm. IR: $\tilde{\nu}$ = 3065, 2960, 2929, 2870, 1583, 1469, 1450, 1435, 1402, 1264, 1185, 1111, 1037, 839 [$\nu(PF_6^-)$], 757, 697, 557 cm^{-1}. $C_{46}H_{45}F_6O_2P_3Pd$ (943.17): calcd. C 58.58, H 4.81; found C 59.17, H 5.42.

[Pd(η^3-C_4H_7)(L7)$_2$]PF_6 (Pd7′): The procedure was the same as that used to prepare **Pd1′**. Starting from **L7** (190 mg, 0.57 mmol) and dimer **D** (43 mg, 0.11 mmol) the desired complex was obtained as a brown solid, yield 177 mg (83 %). ^1H NMR (400 MHz): δ = 7.79 (dd, *J* = 6.0, 3.2 Hz, 1 H), 7.76 (d, *J* = 7.2 Hz, 1 H), 7.68–7.63 (m, 2 H), 7.58–7.43 (m, 4 H), 7.39–7.14 (m, 11 H), 7.12 (d, *J* = 8.0 Hz, 1 H), 6.74 (dd, *J* = 7.2, 4.0 Hz, 1 H), 6.69–6.59 (m, 2 H), 6.31 (t, *J* = 8.8 Hz, 1 H), 5.11 (s, 1 H^s), 4.72 (s, 1 H^s), 3.75 (d, $^3J_{H,P}$ = 10.0 Hz, 1 H^a), 3.72 (d, $^3J_{H,P}$ = 10.4 Hz, 1 H^a), 2.35 (s, 3 H), 1.18 (d, $^3J_{H,P}$ = 15.6 Hz, 9 H), 1.03 (d, $^3J_{H,P}$ = 15.2 Hz, 9 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 155.7–111.3 (C, CH, Ar), 73.4 (d, $J_{C,P}$ = 27.5 Hz, CH_2), 72.4 (d, $J_{C,P}$ = 28.5 Hz, CH_2), 36.9 (d, $^1J_{C,P}$ = 20.6 Hz, C), 35.9 (d, $^1J_{C,P}$ = 21.0 Hz, C), 29.8 (d, $^2J_{C,P}$ = 5.9 Hz, CH_3), 29.5 (d, $^2J_{C,P}$ = 6.6 Hz, CH_3), 23.0 (s, CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +44.4 (d, $^2J_{P,P}$ = 30.5 Hz), +43.8 (d, $^2J_{P,P}$ = 30.9 Hz) ppm. IR: $\tilde{\nu}$ = 3062, 2962, 2869, 1583, 1470, 1449, 1398, 1366, 1264, 1185, 1110, 1094, 1011, 830 [$\nu(PF_6^-)$], 753, 699, 557 cm^{-1}. $C_{48}H_{49}F_6O_2P_3Pd$ (971.22): calcd. C 59.36, H 5.08; found C 58.90, H 5.52.

[Pd(η^3-C_4H_7)(L8)$_2$]PF_6 (Pd8′): The procedure was the same as that used to prepare **Pd1′**. Starting from **L8** (126 mg, 0.27 mmol) and dimer **D** (21 mg, 0.053 mmol) the desired complex was obtained as a brown solid, yield 115 mg (88 %). ^1H NMR (400 MHz): δ = 8.17 (d, *J* = 7.6 Hz, 1 H), 8.15 (d, *J* = 7.2 Hz, 1 H), 7.98 (d, *J* = 7.6 Hz, 1 H), 7.95 (d, *J* = 7.2 Hz, 1 H), 7.79 (t, *J* = 6.4 Hz, 2 H), 7.72–7.68 (m, 3 H), 7.64–7.56 (m, 4 H), 7.41–7.32 (m, 5 H), 7.17 (d, *J* = 8.0 Hz, 1 H), 7.13

(d, J = 8.0 Hz, 1 H), 6.54 (t, J = 7.6 Hz, 1 H), 6.49 (t, J = 7.6 Hz, 1 H), 6.19 (t, J = 8.8 Hz, 1 H), 6.09 (t, J = 8.8 Hz, 1 H), 4.58 (s, 1 H), 4.47 (s, 1 H), 4.40 (s, 1 H), 4.38 (s, 1 H), 4.31 (s, 2 H), 3.96 (s, 1 H), 3.93 (s, 1 H^s), 3.89 (s, 1 H), 3.83 (s, 1 H^s), 3.72 (s, 5 H), 3.55 (s, 5 H), 3.47 (d, $^3J_{H,P}$ = 10.0 Hz, 1 H^a), 3.20 (d, $^3J_{H,P}$ = 10.0 Hz, 1 H^a), 1.86 (s, 3 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 155.2–111.5 (C, CH, Ar), 77.8 (d, $J_{C,P}$ = 27.9 Hz, CH_2), 74.0 (s, CH_2), 73.9–69.7 (m, 8 × CH), 69.5 (s, 5 × CH), 69.3 (s, 5 × CH), 23.4 (s, CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +13.3 (d, $^2J_{P,P}$ = 38.1 Hz), +12.9 (d, $^2J_{P,P}$ = 37.7 Hz) ppm. IR: $\tilde{\nu}$ = 3062, 2956, 1585, 1450, 1437, 1402, 1185, 1162, 1108, 1031, 1002, 839 [$\nu(PF_6^-)$], 754, 696, 557 cm^{-1}. HRMS: calcd. for $C_{60}H_{49}Fe_2O_2P_2Pd$ [M – PF_6] 1081.0935; found 1081.0927.

[Pd(η^3-C_4H_7)(L10)$_2$]PF_6 (Pd10′): The procedure was the same as that used to prepare **Pd1′**. Starting from **L10** (370 mg, 1.21 mmol) and dimer **D** (95 mg, 0.24 mmol) the desired complex was obtained as a brownish solid, yield 350 mg (79 %). ^1H NMR (400 MHz): δ = 8.18–8.12 (m, 4 H), 7.74–7.72 (m, 1 H), 7.66–7.64 (m, 1 H), 7.55–7.31 (m, 13 H), 7.23 (td, J = 7.6, 2.4 Hz, 2 H), 7.17–7.09 (m, 3 H), 3.92 (br. s, 1 H^s), 3.72 (br. s, 1 H^s), 3.61 (d, $^3J_{H,P}$ = 9.6 Hz, 1 H^a), 3.51 (d, $^3J_{H,P}$ = 9.6 Hz, 1 H^a), 2.08 (d, $^2J_{H,P}$ = 8.4 Hz, 3 H), 1.92 (s, 3 H), 1.90 (d, $^2J_{H,P}$ = 8.4 Hz, 3 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 142.6–122.0 (C, CH, Ar), 76.2 (d, $J_{C,P}$ = 28.9 Hz, CH_2), 74.9 (d, $J_{C,P}$ = 29.1 Hz, CH_2), 23.6 (s, CH_3), 13.5 (d, $^1J_{C,P}$ = 27.9 Hz, CH_3), 12.6 (d, $^1J_{C,P}$ = 27.2 Hz, CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +3.3 (d, $^2J_{P,P}$ = 38.2 Hz), +1.1 (d, $^2J_{P,P}$ = 38.4 Hz) ppm. IR: $\tilde{\nu}$ = 3057, 1621, 1437, 1377, 1296, 1251, 1161, 1106, 1078, 839 [$\nu(PF_6^-)$], 753, 693, 557 cm^{-1}. $C_{42}H_{37}F_6P_3PdS_2$ (919.18): calcd. C 54.88, H 4.06, S 6.98; found C 55.08, H 4.33, S 7.02.

[Pd(η^3-C_4H_7)(L11)$_2$]PF_6 (Pd11′): The procedure was the same as that used to prepare **Pd1′**. Starting from **L11** (733 mg, 2.19 mmol) and dimer **D** (166 mg, 0.42 mmol) the desired complex was obtained as a brown solid, yield 310 mg (38 %). ^1H NMR (400 MHz): δ = 8.28 (t, J = 8.8 Hz, 2 H), 8.18 (t, J = 8.4 Hz, 2 H), 7.63–7.44 (m, 10 H), 7.37–7.32 (m, 3 H), 7.24–7.08 (m, 7 H), 4.43 (s, 1 H^s), 4.24 (s, 1 H^s), 3.77 (d, $^3J_{H,P}$ = 9.2 Hz, 1 H^a), 3.53 (d, $^3J_{H,P}$ = 9.6 Hz, 1 H^a), 2.57 (m, 2 H), 1.96 (s, 3 H), 0.90–0.76 (m, 9 H), 0.66 (dd, J = 18.0, 6.8 Hz, 3 H) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 143.0–121.9 (C, CH, Ar), 76.9 (d, $J_{C,P}$ = 32.0 Hz, CH_2), 75.5 (d, $J_{C,P}$ = 28.2 Hz, CH_2), 27.1 (d, $^1J_{C,P}$ = 21.2 Hz, CH), 26.6 (d, $^1J_{C,P}$ = 21.9 Hz, CH), 22.9 (s, CH_3), 18.9 (d, $^2J_{C,P}$ = 4.4 Hz, CH_3), 18.5 (s, 3CH_3) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +26.6 (d, $^2J_{P,P}$ = 32.6 Hz), +24.9 (d, $^2J_{P,P}$ = 32.6 Hz) ppm. IR: $\tilde{\nu}$ = 3057, 2962, 2930, 2870, 1585, 1437, 1375, 1250, 1098, 1078, 1033, 839 [$\nu(PF_6^-)$], 755, 703, 557 cm^{-1}. $C_{46}H_{45}F_6P_3PdS_2$ (975.29): calcd. C 56.65, H 4.65, S 6.57; found C 56.90, H 5.33, S 6.06.

[Pd(η^3-C_4H_7)(L12)$_2$]PF_6 (Pd12′): The procedure was the same as that used to prepare **Pd1′**. Starting from **L12** (100 mg, 0.21 mmol) and dimer **D** (17 mg, 0.043 mmol) the desired complex was obtained as a brown solid, yield 88 mg (93 %). ^1H NMR (400 MHz): δ = 8.03 (t, J = 6.8 Hz, 2 H), 7.90 (t, J = 8.8 Hz, 2 H), 7.72 (t, J = 8.4 Hz, 2 H), 7.61 (t, J = 9.2 Hz, 2 H), 7.53–7.34 (m, 12 H), 7.20–6.97 (m, 4 H), 4.49 (s, 1 H), 4.40 (s, 1 H), 4.35 (s, 2 H), 4.30 (s, 1 H), 4.23 (s, 1 H^s), 4.13 (s, 1 H^s), 4.02 (s, 2 H), 3.96 (s, 1 H), 3.87 (s, 5 H), 3.85 (s, 5 H), 3.74 (d, $^3J_{H,P}$ = 12.8 Hz, 1 H^a), 3.71 (d, $^3J_{H,P}$ = 9.6 Hz, 1 H^a), 2.10 (s, 3 H) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +15.0 (d, $^2J_{P,P}$ = 32.2 Hz), +14.3 (d, $^2J_{P,P}$ = 32.6 Hz) ppm. IR: $\tilde{\nu}$ = 3057, 2957, 1437, 1402, 1376, 1161, 1107, 1033, 840 [$\nu(PF_6^-)$], 754, 696, 557 cm^{-1}. HRMS: calcd. for $C_{60}H_{49}Fe_2P_2PdS_2$ [M – PF_6] 1113.0479; found 1113.0479.

[Pd(η^3-C_4H_7)(L13)$_2$]PF_6 (Pd13′): The procedure was the same as that used to prepare **Pd1′**. Starting from **L13** (240 mg, 0.71 mmol) and dimer **D** (56 mg, 0.14 mmol) the desired complex was obtained as a yellow solid, yield 210 mg (76 %). ^1H NMR (400 MHz): δ = 8.00–6.80 (m, 24 H), 3.73 (br. s, 2 H^s), 3.49 (br. s, 1 H^a), 3.25 (br. s, 1 H^a), 2.03 (s, 3 H), 2.00 (s, 3 H) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +3.4 (d, $^2J_{P,P}$ = 39.7 Hz), +1.5 (d, $^2J_{P,P}$ = 41.1 Hz) ppm. IR: $\tilde{\nu}$ = 3053, 2957, 2919, 1449, 1434, 1381, 1141, 1110, 1028, 888, 832 [$\nu(PF_6^-)$], 748, 693, 557 cm^{-1}. HRMS: calcd. for $C_{23}H_{22}PPdS_2$ [M – PF_6 – **L13**] 498.9935; found 498.9950.

[Pd(η^3-C_4H_7)(κ^2*P,S*-L3)]PF_6 (Pd3″): Complex **Pd3** (148 mg, 0.27 mmol) was dissolved in dichloromethane (20 mL), thallium hexafluorophosphate (101 mg, 0.29 mmol) was added, and the pale yellow suspension was stirred for 2 h. Water (20 mL) was added and the mixture was extracted with dichloromethane (3 × 10 mL). The combined organic phases were washed with water, dried with anhydrous sodium sulfate and filtered, and the solvent was removed under vacuum. The crude product was recrystallised from dichloromethane/hexane, yield 120 mg (67 %). ^1H NMR (400 MHz): δ = 7.89–7.87 (d, J = 7.2 Hz, 2 H, m + M), 7.73–7.70 (m, 5 H, m + M), 7.64–7.41 (m, 17 H, m + M), 5.36 (br. s, 1 H^{ts}, m), 5.31 (br. s, 1 H^{ts}, M), 4.64 (s, 1 H^{cs}, m), 4.31 (s, 1 H^{cs}, M), 4.20 (d, J = 12.0 Hz, 1 H^{ta}, M), 4.11 (d, J = 10.4 Hz, 1 H^{ta}, m), 3.84 (s, 1 H^{ca}, M), 3.78 (d, $^3J_{H,P}$ = 15.6 Hz, 3 H, M), 3.60 (d, $^3J_{H,P}$ = 15.6 Hz, 3 H, m), 3.35 (s, 1 H^{ca}, m), 2.14 (s, 3 H, m), 1.98 (s, 3 H, M) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 139.6–129.3 (C, CH, Ar), 78.9 (d, $^2J_{C,P}$ = 29.8 Hz, CH_2^t, m), 78.4 (d, $^2J_{C,P}$ = 32.4 Hz, CH_2^t, M), 66.1 (s, CH_2^c, M), 65.7 (s, CH_2^c, m), 58.1 (s, CH_3, M), 57.5 (s, CH_3, m), 24.1 (s, CH_3, M), 23.9 (s, CH_3, m) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +138.5 (br. s, m), 136.2 (s, M) ppm. IR: $\tilde{\nu}$ = 3058, 2944, 1436, 1386, 1143, 1109, 1026, 832 [$\nu(PF_6^-)$], 778, 751, 715, 693, 557, 505 cm^{-1}. $C_{23}H_{22}F_6OP_2PdS_2$ (660.88): calcd. C 41.80, H 3.35, S 9.70; found C 41.87, H 3.61, S 9.99.

[Pd(η^3-C_4H_7)(κ^2*P,S*-L13)]BF_4 (Pd13″): The procedure was the same as that followed to prepare **Pd3″**. Starting from **Pd13** (150 mg, 0.28 mmol) and $TlBF_4$ (87 mg, 0.30 mmol), the desired complex was obtained as a yellow solid, yield 110 mg (67 %). ^1H NMR (400 MHz): δ = 7.83 (d, J = 7.6 Hz, 1 H, M), 7.82 (d, J = 7.8 Hz, 1 H, m), 7.72–7.65 (m, 5 H, m + M), 7.64–7.43 (m, 17 H, m + M), 5.28 (br. s, 1 H^{ts}, m), 5.21 (br. s, 1 H^{ts}, M), 4.75 (s, 1 H^{cs}, m), 4.26 (s, 1 H^{cs}, M), 4.05 (d, J = 10.0 Hz, 1 H^{ta}, M), 3.88 (d, J = 10.0 Hz, 1 H^{ta}, m), 3.77 (s, 1 H^{ca}, M), 3.20 (s, 1 H^{ca}, m), 2.35 (d, $^2J_{H,P}$ = 10.0 Hz, 3 H, M), 2.30 (d, $^2J_{H,P}$ = 10.0 Hz, 3 H, m), 2.14 (s, 3 H, m), 1.96 (s, 3 H, M) ppm. $^{13}C\{^1H\}$ NMR (101 MHz): δ = 139.8–129.5 (C, CH, Ar), 77.0 (d, $^2J_{C,P}$ = 31.7 Hz, CH_2^t, m), 76.7 (d, $^2J_{C,P}$ = 31.3 Hz, CH_2^t, M), 67.0 (s, CH_2^c, M), 66.4 (s, CH_2^c, m), 24.0 (s, CH_3, M), 23.8 (s, CH_3, m), 14.4 (d, $^1J_{C,P}$ = 28.7 Hz, CH_3, m), 12.9 (d, $^1J_{C,P}$ = 28.3 Hz, CH_3, M) ppm. $^{31}P\{^1H\}$ NMR (162 MHz): δ = +35.4 (s, M), 34.2 (s, m) ppm. IR: $\tilde{\nu}$ = 3056, 2958, 2918, 1436, 1385, 1283, 1046 [$\nu(BF_4^-)$], 894, 838, 789, 751, 714, 693, 556, 534, 521, 499, 462, 435 cm^{-1}. $C_{23}H_{22}BF_4PPdS_2$ (586.72): calcd. C 47.08, H 3.78, S 10.93; found C 46.89, H 4.05, S 10.41.

Catalytic Procedures

Pd-Catalysed Hydrovinylation: Hydrovinylation reactions were carried out in a stainless steel autoclave fitted with an external jacket connected to an ethanol bath, with the temperature controlled by thermostat to ± 0.5 °C. The internal temperature was monitored with a thermocouple. The Pd precursor (0.020 mmol), styrene (2.08 g, 20 mmol) and $AgBF_4$ (4.3 mg, 0.022 mmol) were dissolved in dichloromethane (15 mL) and stirred for 10 min, protected from light. After the AgCl produced had been filtered off, the solution was quickly placed, by syringe, into the autoclave, which had been purged by successive vacuum/nitrogen cycles and was thermostatted to 25 °C. Ethylene was admitted until a pressure of around 15 bar was reached. After the allotted time, the autoclave was slowly depressurized and aqueous NH_4Cl solution (10 %, 10 mL) was added. The mixture was stirred for 10 min in order to quench the catalyst. The organic layer was separated, dried with Na_2SO_4, filtered through a plug of SiO_2 and subjected to GC analysis.

Pd-Catalysed Allylic Substitutions

(A) Allylic Alkylation with Dimethyl Malonate: The appropriate Pd precursor (0.01 mmol), *trans*-1,3-diphenylprop-2-enyl acetate (*rac*-**I**, 1 mmol), dimethyl malonate (3 mmol), BSA (3 mmol) and KOAc (1 mg) were dissolved, in that precise order, in dichloromethane (5 mL) under nitrogen. The flask was covered with an aluminium foil and left stirring for the allotted time. To quench the reaction, diethyl ether (20 mL) and aqueous ammonium chloride solution (10 %, 20 mL) were added. After extraction, the organic phase was dried with anhydrous sodium sulfate and filtered, and the solvents were removed in vacuo. The crude product was analysed by ^{1}H NMR to estimate the level of conversion. It was then dissolved in ethyl acetate and passed through a column of silica to remove the metallic impurities. The eluent was removed in vacuo and the residue was analysed by NMR and HPLC.

(B) Allylic Amination with Benzylamine: The Pd precursor (0.01 mmol), *trans*-1,3-diphenylprop-2-enyl acetate (*rac*-**I**, 1 mmol) and benzylamine (3 mmol) were dissolved, in that precise order, in dichloromethane (5 mL) under nitrogen. The flask was covered with an aluminium foil and the mixture was stirred for the allotted time. To quench the reaction, diethyl ether (20 mL) and aqueous ammonium chloride solution (10 %, 20 mL) were added. After extraction, the organic phase was dried with anhydrous sodium sulfate and filtered, and the solvents were removed in vacuo. The crude product was analysed by ^{1}H NMR to estimate the level of conversion. It was then dissolved in ethyl acetate and passed through a column of silica to remove the metallic impurities. The eluent was removed in vacuo and the residue was analysed by NMR and HPLC.

Supporting Information: X-ray crystal data with atomic distances and angles for **Pd3''**. NMR spectra of the Pd complexes.

CCDC 1480603 (for **Pd3''**) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre.

Acknowledgments

The authors thank the Ministerio de Economía y Competitividad (MEC) and the Fondo Europeo de Desarrollo Regional (FEDER) (grant number CTQ2015-65040-P) for financial support of this work.

Keywords: Asymmetric catalysis · Hydrovinylation · Allylic substitution · Palladium · P ligands · Phosphane ligands

[1] a) T. V. RajanBabu, *Chem. Rev.* **2003**, *103*, 2845–2860; b) T. V. RajanBabu, *Synlett* **2009**, 853–885; c) T. V. RajanBabu, C. R. Smith, in: *Comprehensive Chirality* (Eds.: E. M. Carreira, Y. Hisashi), Elsevier, Amsterdam, **2012**, p. 355–398; d) R. M. Ceder, A. Grabulosa, G. Muller, M. Rocamora, *Catal. Sci. Technol.* **2013**, *3*, 1446–1464.

[2] a) N. Nomura, J. Jin, H. Park, T. V. RajanBabu, *J. Am. Chem. Soc.* **1998**, *120*, 459–460; b) M. Nandi, J. Jin, T. V. RajanBabu, *J. Am. Chem. Soc.* **1999**, *121*, 9899–9900; c) T. V. RajanBabu, N. Nomura, J. Jin, M. Nandi, H. Park, X. Sun, *J. Org. Chem.* **2003**, *68*, 8431–8446; d) B. Saha, T. V. RajanBabu, *J. Org. Chem.* **2007**, *72*, 2357–2363; e) S. Biswas, A. Zhang, B. Raya, T. V. RajanBabu, *Adv. Synth. Catal.* **2014**, *356*, 2281–2292.

[3] a) M. Hölscher, G. Franciò, W. Leitner, *Organometallics* **2004**, *23*, 5606–5617; b) N. Lassauque, G. Franciò, W. Leitner, *Adv. Synth. Catal.* **2009**, *351*, 3133–3138.

[4] P. Clavero, A. Grabulosa, M. Rocamora, G. Muller, M. Font-Bardia, *Dalton Trans.* **2016**, *45*, 8513–8531.

[5] P. Clavero, A. Grabulosa, M. Font-Bardia, G. Muller, *J. Mol. Catal. A* **2014**, *391*, 183–190.

[6] A. Grabulosa, G. Muller, J. I. Ordinas, A. Mezzetti, M. A. Maestro, M. Font-Bardia, X. Solans, *Organometallics* **2005**, *24*, 4961–4973.

[7] A. Grabulosa, G. Muller, R. Ceder, M. A. Maestro, *Eur. J. Inorg. Chem.* **2010**, 3372–3383.

[8] a) D. Alberti, R. Goddard, K.-R. Pörschke, *Organometallics* **2005**, *24*, 3907–3915; b) R. M. Ceder, C. Garcia, A. Grabulosa, F. Karipcin, G. Muller, M. Rocamora, M. Font-Bardia, X. Solans, *J. Organomet. Chem.* **2007**, *692*, 4005–4019.

[9] P. E. Garrou, *Chem. Rev.* **1981**, *81*, 229–266.

[10] a) J. M. Lovell, R. L. Beddoes, J. A. Joule, *Tetrahedron* **1996**, *52*, 4745–4756; b) S. Ogawa, H. Muraoka, R. Sato, *Tetrahedron Lett.* **2006**, *47*, 2479–2483; c) A. Swist, J. Sloducho, P. Data, M. Lapkowski, *ARKIVOC (Gainesville, FL, U.S.)* **2012**, 193–209; d) M. C. Sheikh, T. Iwasawa, K. Nakajima, A. Kitao, N. Tsubaki, R. Miyatake, T. Yoshimura, H. Morita, *Synthesis* **2014**, *46*, 42–48.

[11] I. H. Filip, E. Gál, I. Lupan, M. Perde Schrepler, P. Lönnecke, M. Surducan, L. Gaina, E. Hey-Hawkins, L. Silaghi-Dumitrescu, *Dalton Trans.* **2015**, *44*, 615–629.

[12] T. V. RajanBabu, N. Nomura, J. Jin, B. Radetich, H. Park, M. Nandi, *Chem. Eur. J.* **1999**, *5*, 1963–1968.

[13] G. Franciò, F. Faraone, W. Leitner, *J. Am. Chem. Soc.* **2002**, *124*, 736–737.

[14] a) R. Bayersdörfer, B. Ganter, U. Englert, W. Keim, D. Vogt, *J. Organomet. Chem.* **1998**, *552*, 187–194; b) R. M. B. Carrilho, G. N. Costa, Â. C. B. Neves, M. M. Pereira, A. Grabulosa, J. C. Bayón, M. Rocamora, G. Muller, *Eur. J. Inorg. Chem.* **2014**, 1034–1041.

[15] a) J. Albert, J. M. Cadena, J. R. Granell, G. Muller, J. I. Ordinas, D. Panyella, C. Puerta, C. Sañudo, P. Valerga, *Organometallics* **1999**, *18*, 3511–3518; b) I. Ayora, R. M. Ceder, M. Espinel, G. Muller, M. Rocamora, M. Serrano, *Organometallics* **2011**, *30*, 115–128; c) A. Grabulosa, A. Mannu, G. Muller, T. Calvet, M. Font-Bardia, *J. Organomet. Chem.* **2011**, *696*, 2338–2345.

[16] L. Rodríguez, O. Rossell, M. Seco, A. Grabulosa, G. Muller, M. Rocamora, *Organometallics* **2006**, *25*, 1368–1376.

[17] a) B. M. Trost, D. L. van Vranken, *Chem. Rev.* **1996**, *96*, 395–422; b) B. M. Trost, M. L. Crawley, *Chem. Rev.* **2003**, *103*, 2921–2943; c) B. Sundararaju, M. Achard, C. Bruneau, *Chem. Soc. Rev.* **2012**, *41*, 4467–4483; d) N. A. Butt, W. Zhang, *Chem. Soc. Rev.* **2015**, *44*, 7929–7967.

[18] M. Ramillien, N. Vanthuyne, M. Jean, D. Gherase, M. Giorgi, J.-V. r. Naubron, P. Piras, C. Roussel, *J. Chromatogr. A* **2012**, *1269*, 82–93.

[19] H. Aït-Haddou, O. Hoarau, D. Cramailére, F. Pezet, J. Daran, G. G. A. Balavoine, *Chem. Eur. J.* **2004**, *10*, 699–707.

[20] Y.-Y. Yan, T. V. RajanBabu, *Org. Lett.* **2000**, *2*, 199–202.

[21] W. L. F. Armarego, C. L. L. Chai, *Purification of Laboratory Chemicals*, 7th ed., Butterworth Heinemann, Oxford, UK, **2013**.

[22] W. T. Dent, R. Long, A. J. Wilkinson, *J. Chem. Soc.* **1964**, 1585–1588.

[23] P. R. Auburn, P. B. Mackenzie, B. Bosnich, *J. Am. Chem. Soc.* **1985**, *107*, 2033–2046.

Received: May 23, 2016
Published Online: August 16, 2016